IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2847
-0.0003 (-0.11%)
Apr 1, 2025, 4:00 PM EST - Market closed

IGC Pharma Statistics

Total Valuation

IGC Pharma has a market cap or net worth of $22.69 million. The enterprise value is $22.51 million.

Market Cap 22.69M
Enterprise Value 22.51M

Important Dates

The last earnings date was Tuesday, February 18, 2025, before market open.

Earnings Date Feb 18, 2025
Ex-Dividend Date n/a

Share Statistics

IGC Pharma has 79.69 million shares outstanding. The number of shares has increased by 29.68% in one year.

Current Share Class 79.69M
Shares Outstanding 79.69M
Shares Change (YoY) +29.68%
Shares Change (QoQ) +2.14%
Owned by Insiders (%) 9.29%
Owned by Institutions (%) 20.91%
Float 72.28M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 16.76
Forward PS 17.19
PB Ratio 3.56
P/TBV Ratio 5.17
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 18.21
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.04.

Current Ratio 1.15
Quick Ratio 0.21
Debt / Equity 0.04
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -115.06% and return on invested capital (ROIC) is -69.70%.

Return on Equity (ROE) -115.06%
Return on Assets (ROA) -54.70%
Return on Invested Capital (ROIC) -69.70%
Return on Capital Employed (ROCE) -138.61%
Revenue Per Employee $18,448
Profits Per Employee -$131,478
Employee Count 67
Asset Turnover 0.12
Inventory Turnover 0.36

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -26.75% in the last 52 weeks. The beta is 1.43, so IGC Pharma's price volatility has been higher than the market average.

Beta (5Y) 1.43
52-Week Price Change -26.75%
50-Day Moving Average 0.31
200-Day Moving Average 0.37
Relative Strength Index (RSI) 43.96
Average Volume (20 Days) 403,010

Short Selling Information

The latest short interest is 974,024, so 1.22% of the outstanding shares have been sold short.

Short Interest 974,024
Short Previous Month 813,399
Short % of Shares Out 1.22%
Short % of Float 1.35%
Short Ratio (days to cover) 2.30

Income Statement

In the last 12 months, IGC Pharma had revenue of $1.24 million and -$8.81 million in losses. Loss per share was -$0.12.

Revenue 1.24M
Gross Profit 636,000
Operating Income -8.90M
Pretax Income -13.30M
Net Income -8.81M
EBITDA -8.27M
EBIT -8.90M
Loss Per Share -$0.12
Full Income Statement

Balance Sheet

The company has $470,000 in cash and $270,000 in debt, giving a net cash position of $200,000 or $0.00 per share.

Cash & Cash Equivalents 470,000
Total Debt 270,000
Net Cash 200,000
Net Cash Per Share $0.00
Equity (Book Value) 6.26M
Book Value Per Share 0.08
Working Capital 394,000
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$4.59 million and capital expenditures -$109,000, giving a free cash flow of -$4.70 million.

Operating Cash Flow -4.59M
Capital Expenditures -109,000
Free Cash Flow -4.70M
FCF Per Share -$0.06
Full Cash Flow Statement

Margins

Gross Margin 51.46%
Operating Margin -720.06%
Pretax Margin -712.70%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

IGC Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -29.68%
Shareholder Yield -29.68%
Earnings Yield -38.79%
FCF Yield -20.70%

Analyst Forecast

The average price target for IGC Pharma is $3.88, which is 1,262.84% higher than the current price. The consensus rating is "Strong Buy".

Price Target $3.88
Price Target Difference 1,262.84%
Analyst Consensus Strong Buy
Analyst Count 2
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on April 19, 2013. It was a reverse split with a ratio of 0.1:1.

Last Split Date Apr 19, 2013
Split Type Reverse
Split Ratio 0.1:1

Scores

IGC Pharma has an Altman Z-Score of -15.44 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -15.44
Piotroski F-Score 4